Insilico Medicine projected record first-half revenue and a return to profitability outlook, driven by its partnership revenue and pipeline progress, as its lead program advanced late-stage development. The company expects first-half net profit and adjusted non-IFRS net profit to move sharply higher year over year. Insilico forecast first-half 2026 revenue between about $102.5 million and $106.5 million, a more than doubling versus a year earlier, alongside guidance that the company finishes H1 2026 in the black. The company also pointed to strengthened cash levels, despite prior losses attributed in part to non-cash fair value changes tied to prior financings. The update matters to investors because it links pipeline progression and collaboration performance to financial execution, rather than relying purely on future capital raises. Insilico’s statement signals confidence in sustaining profitability as the company pushes its first late-stage program forward.